Literature DB >> 23948509

Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.

G Rubini1, C Altini1, A Notaristefano1, N Merenda1, D Rubini1, A A Stabile Ianora2, A Niccoli Asabella3.   

Abstract

OBJECTIVES: To investigate the role of whole-body fluorine-18-2-deoxy-2-fluoro-d-glucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in the identification of peritoneal carcinomatosis in patients with ovarian cancer (OC).
MATERIAL AND METHODS: Seventy-nine patients with histologically proven stages III-IV OC who underwent (18)F-FDG PET/CT were studied retrospectively. We considered group A as 51 patients who also underwent computed-tomography with contrast-enhancement (CECT), and group B as 35 patients who had also been tested for biomarker Ca-125. Sensitivity, specificity, accuracy, positive predictive values (PPV) and negative predictive values (NPV) of (18)F-FDG PET/CT as compared to CECT and to Ca-125 were evaluated.
RESULTS: (18)F-FDG PET/CT' sensitivity, specificity, accuracy, PPV and NPV for all 79 patients were: 85%, 92.31%, 88.61%, 91.89% and 85.71%, respectively. (18)F-FDG PET/CT sensitivity in group A was 78.6%, while it was 53.6% for CECT. (18)F-FDG PET/CT specificity, calculated in the same group, was 91.3%, while that of CECT was 60.9% (statistically significant difference, McNemar 4, P=0.039). Accuracy was 84.3% and 56.9%, respectively. (18)F-FDG PET/CT' sensitivity in group B was 86.4%, while that of Ca-125 was 81.8% (no statistical difference, McNemar 0, P=1). (18)F-FDG PET/CT specificity in group B was 84.6% while that of Ca-125 was 38.5% (clear but not statistically significant difference, McNemar 3.12, P=0.070). Accuracy calculated in the same group was 85.7% for (18)F-FDG PET/CT and 65.7% for Ca-125.
CONCLUSION: (18)F-FDG PET/CT is a useful diagnostic tool when peritoneal biopsy cannot be performed and it can better select those who are candidates for adjuvant chemotherapy.
Copyright © 2013 Elsevier España, S.L. and SEMNIM. All rights reserved.

Entities:  

Keywords:  (18)F-FDG PET/CT; CT contraste; Ca-125; Contrast enhanced CT; Cáncer de ovario; Metástasis peritoneales; Ovarian cancer; Peritoneal metastases

Mesh:

Substances:

Year:  2013        PMID: 23948509     DOI: 10.1016/j.remn.2013.06.008

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  10 in total

Review 1.  Diagnostic accuracy of 18F-FDG PET/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis.

Authors:  Seong-Jang Kim; Sang-Woo Lee
Journal:  Br J Radiol       Date:  2017-11-21       Impact factor: 3.039

Review 2.  Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis.

Authors:  Andrea Laghi; Davide Bellini; Marco Rengo; Fabio Accarpio; Damiano Caruso; Daniele Biacchi; Angelo Di Giorgio; Paolo Sammartino
Journal:  Radiol Med       Date:  2016-09-19       Impact factor: 3.469

3.  The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

Authors:  Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-19       Impact factor: 9.236

4.  Is MDCT an accurate tool to differentiate between benign and malignant etiology in diffuse peritoneal disease?

Authors:  Shyjumon George; Kirthi Sathyakumar; Mandeep Singh Bindra; Anu Eapen
Journal:  Abdom Radiol (NY)       Date:  2022-08-17

5.  Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer.

Authors:  Halil Kömek; Canan Can; İhsan Kaplan; Cihan Gündoğan; Ferat Kepenek; Hüseyin Karaoglan; Aykut Demirkıran; Senar Ebinç; Yunus Güzel; Ebubekir Gündeş
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-17       Impact factor: 10.057

Review 6.  Peritoneal malignancy: anatomy, pathophysiology and an update on modern day imaging.

Authors:  Jack W Power; Philip J Dempsey; Andrew Yates; Helen Fenlon; Jurgen Mulsow; Conor Shields; Carmel G Cronin
Journal:  Br J Radiol       Date:  2021-12-08       Impact factor: 3.629

Review 7.  Systematic Review on the Accuracy of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging in the Management of Ovarian Cancer: Is Functional Information Really Needed?

Authors:  Subapriya Suppiah; Wing Liong Chang; Hasyma Abu Hassan; Chalermrat Kaewput; Andi Anggeriana Andi Asri; Fathinul Fikri Ahmad Saad; Abdul Jalil Nordin; Sobhan Vinjamuri
Journal:  World J Nucl Med       Date:  2017 Jul-Sep

8.  Radiomics Analysis of PET and CT Components of 18F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer.

Authors:  Xihai Wang; Zaiming Lu
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

9.  Multiparameter MRI Radiomics Model Predicts Preoperative Peritoneal Carcinomatosis in Ovarian Cancer.

Authors:  Xiao Yu Yu; Jialiang Ren; Yushan Jia; Hui Wu; Guangming Niu; Aishi Liu; Yang Gao; Fene Hao; Lizhi Xie
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

10.  Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.

Authors:  Daniela Rusu; Thomas Carlier; Mathilde Colombié; Dorothée Goulon; Vincent Fleury; Nicolas Rousseau; Dominique Berton-Rigaud; Isabelle Jaffre; Françoise Kraeber-Bodéré; Loic Campion; Caroline Rousseau
Journal:  Front Med (Lausanne)       Date:  2015-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.